HBM Healthcare Investments publishes a net asset value per share (NAV) of CHF 285.53 as of March 31, 2022

0

[ad_1]

After the record result of the previous year, HBM Healthcare Investments experienced a slight decline in value during the financial year 2021/22 ended March 31, 2022. The net asset value (NAV) per share fell by 3 .6% to CHF285.53. The share price fell disproportionately by 13.2% to CHF 276.00.

The healthcare sector presented a mixed picture in terms of performance during the year under review. While the MSCI World Health Care Index, which primarily tracks large-cap pharmaceutical and medtech companies, rose 13%, market capitalizations of biotech companies (Nasdaq Biotechnology Index -13% and SPDR S&P Biotech ETF -35%) decreased, in some cases significantly.

Based on the NAV as of March 31, 2022, HBM Healthcare Investments expects an annual loss of around CHF 80 million (previous year: annual profit of CHF 756 million). For an investment company, net income reflects changes in the value of equity interests held.

With a well-balanced mix of private and listed companies and cash and cash equivalents of over CHF 220 million, the portfolio remains well positioned for long-term value growth.

This result is preliminary and unaudited based on the current status of the closing process. The final annual result will be published on Friday May 6, 2022.

[ad_2]
Source link

Share.

Comments are closed.